drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (biologic drug)
drug_description
HER2-targeted antibody–drug conjugate composed of a humanized anti-HER2 IgG1 (disitamab) linked via a cleavable linker to the cytotoxic payload MMAE. After binding ERBB2 (HER2) on tumor cells and internalization, MMAE is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; the Fc region may mediate ADCC and bystander killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Disitamab vedotin targets HER2 (ERBB2) on tumor cells; after binding and internalization, its cleavable linker releases the microtubule poison MMAE, which inhibits tubulin polymerization causing G2/M arrest and apoptosis. The IgG1 Fc may also mediate ADCC and enable bystander killing.
drug_name
RC48-ADC (disitamab vedotin)
nct_id_drug_ref
NCT05996952